Published in AIDS Weekly, June 17th, 1996
Patient enrollment in this study, which is sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), has commenced and will include 560 people infected with HIV once enrollment is completed. In this study, three preparations of LDOAI, including Alferon LDO and two other brands of LDOAI from foreign sources are compared to a placebo.
The trial design was the result of joint...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.